CD274 and non-small cell lung carcinoma: Patients with advanced NSCLC and PD‐L1 TPS > 50% benefit from first‐line treatment based on the anti‐PD‐1 agent pembrolizumab, obtaining improved survival and reduced adverse effects compared to standard chemotherapy.12